NautaDutilh advised CureVac N.V., a clinical-stage biopharmaceutical company, on its definitive agreement with BioNTech SE for a strategic all-stock acquisition valued at approximately USD 1.25 billion.
The transaction involves BioNTech acquiring all outstanding CureVac shares through a public exchange offer. The deal brings together two complementary biotech companies with a strong focus on mRNA-based medicines for oncology and infectious diseases.
“We have supported CureVac since their IPO, throughout their journey as a publicly listed company, and now in this transaction that will help drive future innovation and value creation”
Next to Paul, our team consisted of Stefan Wissing, Nina Kielman, Daniël Kuiper, Daan Hagelstein, Sanne Mesu, Dirk Panis, Mike Koudenburg, Ash Beesemer, Niels van Ham, Brian Cuijpers and Sien Vandezande.
